ReviewDiagnostic and interventional radiology (Ankara, Turkey)2023
Drug-induced lung disease: a brief update for radiologists.
Review in Diagnostic and interventional radiology (Ankara, Turkey), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer.The oncologist · 2026Observational
- Artificial intelligence and radiomics in drug-induced interstitial lung disease.ERJ open research · 2026Review
- Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials.NPJ breast cancer · 2026Article
- CT findings of lung injury during breast cancer treatment.Breast cancer (Tokyo, Japan) · 2026Review
- Drug-Induced Interstitial Lung Disease in Lung Cancer Patients.Respiration; international review of thoracic diseases · 2026Review
- The reverse halo sign in emergency chest CT: A diagnostic guide across diverse pulmonary conditions.Emergency radiology · 2025Review
- Centrilobular ground-glass nodule pattern in acute myeloid leukemia patients receiving cytosine arabinoside chemotherapy: an important form of drug-induced lung disease.Diagnostic and interventional radiology (Ankara, Turkey) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary adverse events and drug-induced lung disease (DILD) can occur when treating many conditions. The incidence of DILDs in clinical practice and the variety of radiological findings have increased, mainly due to the increased use of novel therapeutic agents. It is crucial to determine whether the newly emerging clinical and imaging findings in these patients are due to the progression of the underlying disease, infection, pulmonary edema, or drug use, as this will change the patient management. Although the diagnosis of DILD is usually obtained by excluding other possible causes, radiologists should be aware of the imaging findings of DILD. This article reviews the essential radiological results of DILD and summarizes the critical clinical and imaging findings with an emphasis on novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.